AD0-E605 · Question #74
A retail company uses Adobe RT-CDP and receives an alert about a quota breach for profile activations. What should the administrator do first?
The correct answer is B. Monitor license usage to identify which profiles exceed the quota.. When a quota breach alert fires in Adobe RT-CDP, the administrator's first responsibility is to monitor license usage (B) - diagnosing the scope of the problem before taking any action. The License Usage dashboard shows which profile counts or activation volumes are exceeding ent
Question
A retail company uses Adobe RT-CDP and receives an alert about a quota breach for profile activations. What should the administrator do first?
Options
- ADisable all active segments to reduce profile usage.
- BMonitor license usage to identify which profiles exceed the quota.
- CExport all profiles to an external system.
- DReconfigure batch ingestion workflows to bypass profile updates.
How the community answered
(36 responses)- A3% (1)
- B75% (27)
- C14% (5)
- D8% (3)
Explanation
When a quota breach alert fires in Adobe RT-CDP, the administrator's first responsibility is to monitor license usage (B) - diagnosing the scope of the problem before taking any action. The License Usage dashboard shows which profile counts or activation volumes are exceeding entitlements, giving the admin the data needed to make an informed decision.
Why the distractors are wrong:
- A is a drastic, business-disrupting move that should only be considered after investigation confirms it's necessary.
- C is irrelevant to a quota breach - exporting profiles doesn't reduce platform consumption or address the underlying limit.
- D bypassing ingestion workflows is both incorrect (batch ingestion isn't the direct cause of activation quota breaches) and potentially harmful to data integrity.
Memory tip: Think "diagnose before you act." In any quota or license scenario, the answer that involves observing and measuring is almost always the correct first step - just as a doctor checks vitals before prescribing treatment.
Topics
Community Discussion
No community discussion yet for this question.